{"id":10061,"date":"2026-02-24T06:42:08","date_gmt":"2026-02-24T12:42:08","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10061"},"modified":"2026-02-24T06:49:19","modified_gmt":"2026-02-24T12:49:19","slug":"nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","title":{"rendered":"Los an\u00e1lisis cl\u00ednicos post hoc de Nanoscope Therapeutics se presentar\u00e1n en la reuni\u00f3n anual de la Macula Society de 2026."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

La Dra. Christine N. Kay presentar\u00e1 un an\u00e1lisis multivariante de los datos de 3 a\u00f1os de los estudios RESTORE y REMAIN, identificando las caracter\u00edsticas del paciente y de la enfermedad asociadas con los mejores resultados en pacientes con retinosis pigmentaria tras la terapia g\u00e9nica optogen\u00e9tica MCO-010.<\/strong><\/em><\/h3>

DALLAS<\/span>,\u00a024 de febrero de 2026<\/span>\u00a0 \u2014 Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que nuevos an\u00e1lisis cl\u00ednicos post-hoc de su principal terapia optogen\u00e9tica, MCO-010, se presentar\u00e1n en el\u00a0Reuni\u00f3n Anual de la Sociedad de la M\u00e1cula 2026\u00a0<\/b>que tendr\u00e1 lugar del 25 al 28 de febrero de 2026 en<\/b>\u00a0San Diego, California<\/b>.<\/p>

Christine N. Kay, Doctora en Medicina.<\/a><\/b>, El director de investigaci\u00f3n cl\u00ednica y gen\u00e9tica retiniana de Vitreoretinal Associates en Gainesville, Florida, presentar\u00e1 nuevos an\u00e1lisis del seguimiento a largo plazo de los datos de un ensayo cl\u00ednico aleatorizado de fase 2b\/3 de tres a\u00f1os, examinando las caracter\u00edsticas de los pacientes y de la enfermedad asociadas con los mejores resultados. Esta es la primera vez que se presentan estos datos, lo que ofrece a los m\u00e9dicos un marco m\u00e1s completo para comprender los efectos del tratamiento \u00fanico con MCO-010 en pacientes con retinosis pigmentaria (RP) que presentan una p\u00e9rdida visual grave.<\/p>

Detalles de la presentaci\u00f3n:<\/b><\/p>

Presentador:\u00a0<\/b>Christine N. Kay, Doctora en Medicina.
T\u00edtulo:\u00a0<\/b>Resultados de la mejora de la visi\u00f3n en la retinosis pigmentaria: an\u00e1lisis multivariante a partir de datos de 3 a\u00f1os de los estudios RESTORE y REMAIN de la terapia g\u00e9nica optogen\u00e9tica MCO-010.
<\/i>Sesi\u00f3n:\u00a0<\/b>Distrofia Hereditaria I: Ensayos Cl\u00ednicos y M\u00e1s All\u00e1
Fecha y hora:\u00a0<\/b>Viernes, 27 de febrero | 7:30 - 7:35<\/p>

\u201cEstos an\u00e1lisis representan un importante paso adelante para comprender los datos del ensayo cl\u00ednico de fase 3 de MCO-010 en retinosis pigmentaria\u201d, afirm\u00f3 el Dr. Kay.<\/b>\u00a0\u201cAl examinar las caracter\u00edsticas de los pacientes que obtuvieron los mejores resultados durante los tres a\u00f1os de seguimiento en los estudios RESTORE y REMAIN, podemos empezar a comprender c\u00f3mo se puede utilizar la terapia en pacientes en la vida real, si se aprueba.\u201d<\/p>

\u201cLos an\u00e1lisis multivariantes del Dr. Kay a\u00f1aden una dimensi\u00f3n cl\u00ednicamente significativa a lo que ya es un conjunto de datos de referencia\u201d, dijo.\u00a0<\/b>Samuel Barone, Doctor en Medicina.<\/a><\/b>, Director M\u00e9dico de Nanoscope Therapeutics.<\/b>\u00a0\u201cNos enorgullece presentar este trabajo en la Reuni\u00f3n Anual de la Macula Society, donde destacados especialistas en retina podr\u00e1n analizar directamente los hallazgos mientras continuamos con nuestro proceso de solicitud de licencia biol\u00f3gica (BLA) para MCO-010, que potencialmente ofrece la primera terapia aprobada para pacientes con retinosis pigmentaria que sufren una p\u00e9rdida grave de visi\u00f3n.\u201d<\/p>

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se est\u00e1 llevando a cabo una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en 2026. MCO-010 ha recibido las designaciones de V\u00eda R\u00e1pida y Medicamento Hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de EMA de Medicamento Hu\u00e9rfano para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 tambi\u00e9n ha recibido las designaciones de Sakigake (Pionero) y Medicamento Hu\u00e9rfano en Jap\u00f3n por parte del MHLW. Tambi\u00e9n se espera que un programa de Fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Nanoscope Therapeutics, Inc
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Dr. Christine N. Kay to Present Multivariant Analysis of 3-Year RESTORE and REMAIN Data,\u00a0Identifying Patient and Disease Characteristics Associated with Best Outcomes in Retinitis Pigmentosa Patients Following MCO-010 Optogenetic Gene Therapy DALLAS,\u00a0Feb. 24, 2026\u00a0 \u2014 Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and […]<\/p>\n","protected":false},"author":1,"featured_media":10062,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T12:42:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T12:49:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting\",\"datePublished\":\"2026-02-24T12:42:08+00:00\",\"dateModified\":\"2026-02-24T12:49:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"},\"wordCount\":625,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"datePublished\":\"2026-02-24T12:42:08+00:00\",\"dateModified\":\"2026-02-24T12:49:19+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Los an\u00e1lisis cl\u00ednicos post hoc de Nanoscope Therapeutics se presentar\u00e1n en la reuni\u00f3n anual de la Macula Society de 2026.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-02-24T12:42:08+00:00","article_modified_time":"2026-02-24T12:49:19+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting","datePublished":"2026-02-24T12:42:08+00:00","dateModified":"2026-02-24T12:49:19+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"},"wordCount":625,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","name":"Los an\u00e1lisis cl\u00ednicos post hoc de Nanoscope Therapeutics se presentar\u00e1n en la reuni\u00f3n anual de la Macula Society de 2026.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","datePublished":"2026-02-24T12:42:08+00:00","dateModified":"2026-02-24T12:49:19+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10061"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10061\/revisions"}],"predecessor-version":[{"id":10066,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10061\/revisions\/10066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10062"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}